Fluticasone Furoate

CHEMBL1676 Phase 4 Onaylandı Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
538.6 g/mol
LogP
4.8
Phase
4

This inhaled or intranasal corticosteroid reduces inflammation in the airways and nasal passages to control asthma and allergic rhinitis symptoms. It is a potent steroid with once-daily dosing due to its high receptor affinity and prolonged duration of action.

Moleküler Ağırlık

538,6000 g/mol

LogP

4,80

TPSA

119,00 Ų

Lipinski RO5

Geçer

Terapötik Alanlar

Etki Mekanizması

Binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene transcription. This suppresses multiple inflammatory genes encoding cytokines, chemokines, and adhesion molecules while inducing anti-inflammatory proteins.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene transcription. This suppresses multiple inflammatory genes encoding cytokines, chemokines, and adhesion molecules while inducing anti-inflammatory proteins.

2D Yapı

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF

InChI

InChI=1S/C27H29F3O6S/c1-14-9-16-17-11-19(29)18-10-15(31)6-7-24(18,2)26(17,30)21(32)12-25(16,3)27(14,23(34)37-13-28)36-22(33)20-5-4-8-35-20/h4-8,10,14,16-17,19,21,32H,9,11-13H2,1-3H3/t14-,16+,17+,19+,21+,24+,25+,26+,27+/m1/s1

Molecular Formula

C27H29F3O6S

HBD / HBA

1 / 10

Döndürülebilir Bağlar

6

Ağır Atomlar

37

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

This inhaled or intranasal corticosteroid reduces inflammation in the airways and nasal passages to control asthma and allergic rhinitis symptoms. It is a potent steroid with once-daily dosing due to its high receptor affinity and prolonged duration of action.

Binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene transcription. This suppresses multiple inflammatory genes encoding cytokines, chemokines, and adhesion molecules while inducing anti-inflammatory proteins.

Yes, Fluticasone Furoate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1676. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 9854489. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.